Linerixibat

Medication From Wikipedia, the free encyclopedia

Linerixibat, sold under the brand name Lynavoy, is a medication used for the treatment of cholestatic pruritus. Linerixibat is an ileal bile acid transporter (IBAT) inhibitor.[1][2] It is taken by mouth.[1]

Trade namesLynavoy
Other namesGSK-2330672
AHFS/Drugs.comMonograph
MedlinePlusa626054
Quick facts Clinical data, Trade names ...
Linerixibat
Clinical data
Trade namesLynavoy
Other namesGSK-2330672
AHFS/Drugs.comMonograph
MedlinePlusa626054
License data
Routes of
administration		By mouth
Drug classIleal bile acid transporter inhibitor
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC28H38N2O7S
Molar mass546.68 g·mol−1
3D model (JSmol)
  • CCCC[C@@]1(CS(=O)(=O)C2=C(C=C(C(=C2)CNC(CC(=O)O)CC(=O)O)OC)[C@H](N1)C3=CC=CC=C3)CC
  • InChI=1S/C28H38N2O7S/c1-4-6-12-28(5-2)18-38(35,36)24-13-20(17-29-21(14-25(31)32)15-26(33)34)23(37-3)16-22(24)27(30-28)19-10-8-7-9-11-19/h7-11,13,16,21,27,29-30H,4-6,12,14-15,17-18H2,1-3H3,(H,31,32)(H,33,34)/t27-,28-/m1/s1
  • Key:CZGVOBIGEBDYTP-VSGBNLITSA-N
Close

Linerixibat was approved for medical use in the United States in March 2026.[3][4][5]

Medical uses

Linerixibat is indicated for the treatment of cholestatic pruritus associated with primary biliary cholangitis in adults.[1]

Society and culture

Linerixibat was approved for medical use in the United States in March 2026.[4]

Names

Linerixibat is the international nonproprietary name.[6]

Linerixibat is sold under the brand name Lynavoy.[7]

References

Related Articles

Wikiwand AI